Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML)

Nepsilon-carboxymethyllysine (CML) is the major non-cross linking advanced glycation end product (AGE). CML is elevated in diabetic patients and apparent in atherosclerotic lesions. AGEs are associated with hypertension and arterial stiffness potentially by qualitative changes of elastic fibers. We...

Full description

Saved in:
Bibliographic Details
Published inCardiovascular diabetology Vol. 8; p. 45
Main Authors Baumann, Marcus, Richart, Tom, Sollinger, Daniel, Pelisek, Jaroslav, Roos, Marcel, Kouznetsova, Tatiana, Eckstein, Hans-Henning, Heemann, Uwe, Staessen, Jan A
Format Journal Article
LanguageEnglish
Published England 06.08.2009
Subjects
Online AccessGet full text
ISSN1475-2840
1475-2840
DOI10.1186/1475-2840-8-45

Cover

Abstract Nepsilon-carboxymethyllysine (CML) is the major non-cross linking advanced glycation end product (AGE). CML is elevated in diabetic patients and apparent in atherosclerotic lesions. AGEs are associated with hypertension and arterial stiffness potentially by qualitative changes of elastic fibers. We investigated whether CML affects carotid and aortic properties in normoglycemic subjects. Hundred-two subjects (age 48.2+/-11.3 years) of the FLEMENGHO study were stratified according to the median of the plasma CML level (200.8 ng/ml; 25th percentile: 181.6 ng/ml, 75th percentile: 226.1 ng/ml) into "high CML" versus "low CML" as determined by ELISA. Local carotid artery properties, carotid intima media thickness (IMT), aortic pulse wave velocity (PWV), blood pressure and fetuin-A were analyzed. In 26 patients after carotidectomy, CML was visualized using immunohistochemistry. According to the CML median, groups were similar for anthropometric and biochemical data. Carotid diameter was enlarged in the "high" CML group (485.7+/-122.2 versus 421.2+/-133.2 microm; P<0.05), in particular in participants with elevated blood pressure and with "high" CML ("low" CML: 377.9+/-122.2 microm and "high" CML: 514.5+/-151.6 microm; P<0.001). CML was associated fetuin-A as marker of vascular inflammation in the whole cohort (r=0.28; P<0.01) and with carotid diameter in hypertensive subjects (r=0.42; P<0.01). CML level had no effect on aortic stiffness. CML was detected in the subendothelial space of human carotid arteries. In normoglycemic subjects CML was associated with carotid diameter without adaptive changes of elastic properties and with fetuin-A as vascular inflammation marker, in particular in subjects with elevated blood pressure. This may suggest qualitative changes of elastic fibers resulting in a defective mechanotransduction, in particular as CML is present in human carotid arteries.
AbstractList Nepsilon-carboxymethyllysine (CML) is the major non-cross linking advanced glycation end product (AGE). CML is elevated in diabetic patients and apparent in atherosclerotic lesions. AGEs are associated with hypertension and arterial stiffness potentially by qualitative changes of elastic fibers. We investigated whether CML affects carotid and aortic properties in normoglycemic subjects.BACKGROUNDNepsilon-carboxymethyllysine (CML) is the major non-cross linking advanced glycation end product (AGE). CML is elevated in diabetic patients and apparent in atherosclerotic lesions. AGEs are associated with hypertension and arterial stiffness potentially by qualitative changes of elastic fibers. We investigated whether CML affects carotid and aortic properties in normoglycemic subjects.Hundred-two subjects (age 48.2+/-11.3 years) of the FLEMENGHO study were stratified according to the median of the plasma CML level (200.8 ng/ml; 25th percentile: 181.6 ng/ml, 75th percentile: 226.1 ng/ml) into "high CML" versus "low CML" as determined by ELISA. Local carotid artery properties, carotid intima media thickness (IMT), aortic pulse wave velocity (PWV), blood pressure and fetuin-A were analyzed. In 26 patients after carotidectomy, CML was visualized using immunohistochemistry.METHODSHundred-two subjects (age 48.2+/-11.3 years) of the FLEMENGHO study were stratified according to the median of the plasma CML level (200.8 ng/ml; 25th percentile: 181.6 ng/ml, 75th percentile: 226.1 ng/ml) into "high CML" versus "low CML" as determined by ELISA. Local carotid artery properties, carotid intima media thickness (IMT), aortic pulse wave velocity (PWV), blood pressure and fetuin-A were analyzed. In 26 patients after carotidectomy, CML was visualized using immunohistochemistry.According to the CML median, groups were similar for anthropometric and biochemical data. Carotid diameter was enlarged in the "high" CML group (485.7+/-122.2 versus 421.2+/-133.2 microm; P<0.05), in particular in participants with elevated blood pressure and with "high" CML ("low" CML: 377.9+/-122.2 microm and "high" CML: 514.5+/-151.6 microm; P<0.001). CML was associated fetuin-A as marker of vascular inflammation in the whole cohort (r=0.28; P<0.01) and with carotid diameter in hypertensive subjects (r=0.42; P<0.01). CML level had no effect on aortic stiffness. CML was detected in the subendothelial space of human carotid arteries.RESULTSAccording to the CML median, groups were similar for anthropometric and biochemical data. Carotid diameter was enlarged in the "high" CML group (485.7+/-122.2 versus 421.2+/-133.2 microm; P<0.05), in particular in participants with elevated blood pressure and with "high" CML ("low" CML: 377.9+/-122.2 microm and "high" CML: 514.5+/-151.6 microm; P<0.001). CML was associated fetuin-A as marker of vascular inflammation in the whole cohort (r=0.28; P<0.01) and with carotid diameter in hypertensive subjects (r=0.42; P<0.01). CML level had no effect on aortic stiffness. CML was detected in the subendothelial space of human carotid arteries.In normoglycemic subjects CML was associated with carotid diameter without adaptive changes of elastic properties and with fetuin-A as vascular inflammation marker, in particular in subjects with elevated blood pressure. This may suggest qualitative changes of elastic fibers resulting in a defective mechanotransduction, in particular as CML is present in human carotid arteries.CONCLUSIONIn normoglycemic subjects CML was associated with carotid diameter without adaptive changes of elastic properties and with fetuin-A as vascular inflammation marker, in particular in subjects with elevated blood pressure. This may suggest qualitative changes of elastic fibers resulting in a defective mechanotransduction, in particular as CML is present in human carotid arteries.
Nepsilon-carboxymethyllysine (CML) is the major non-cross linking advanced glycation end product (AGE). CML is elevated in diabetic patients and apparent in atherosclerotic lesions. AGEs are associated with hypertension and arterial stiffness potentially by qualitative changes of elastic fibers. We investigated whether CML affects carotid and aortic properties in normoglycemic subjects. Hundred-two subjects (age 48.2+/-11.3 years) of the FLEMENGHO study were stratified according to the median of the plasma CML level (200.8 ng/ml; 25th percentile: 181.6 ng/ml, 75th percentile: 226.1 ng/ml) into "high CML" versus "low CML" as determined by ELISA. Local carotid artery properties, carotid intima media thickness (IMT), aortic pulse wave velocity (PWV), blood pressure and fetuin-A were analyzed. In 26 patients after carotidectomy, CML was visualized using immunohistochemistry. According to the CML median, groups were similar for anthropometric and biochemical data. Carotid diameter was enlarged in the "high" CML group (485.7+/-122.2 versus 421.2+/-133.2 microm; P<0.05), in particular in participants with elevated blood pressure and with "high" CML ("low" CML: 377.9+/-122.2 microm and "high" CML: 514.5+/-151.6 microm; P<0.001). CML was associated fetuin-A as marker of vascular inflammation in the whole cohort (r=0.28; P<0.01) and with carotid diameter in hypertensive subjects (r=0.42; P<0.01). CML level had no effect on aortic stiffness. CML was detected in the subendothelial space of human carotid arteries. In normoglycemic subjects CML was associated with carotid diameter without adaptive changes of elastic properties and with fetuin-A as vascular inflammation marker, in particular in subjects with elevated blood pressure. This may suggest qualitative changes of elastic fibers resulting in a defective mechanotransduction, in particular as CML is present in human carotid arteries.
Author Eckstein, Hans-Henning
Staessen, Jan A
Pelisek, Jaroslav
Roos, Marcel
Kouznetsova, Tatiana
Richart, Tom
Sollinger, Daniel
Baumann, Marcus
Heemann, Uwe
Author_xml – sequence: 1
  givenname: Marcus
  surname: Baumann
  fullname: Baumann, Marcus
  email: marcus.baumann@lrz.tum.de
  organization: Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. marcus.baumann@lrz.tum.de
– sequence: 2
  givenname: Tom
  surname: Richart
  fullname: Richart, Tom
– sequence: 3
  givenname: Daniel
  surname: Sollinger
  fullname: Sollinger, Daniel
– sequence: 4
  givenname: Jaroslav
  surname: Pelisek
  fullname: Pelisek, Jaroslav
– sequence: 5
  givenname: Marcel
  surname: Roos
  fullname: Roos, Marcel
– sequence: 6
  givenname: Tatiana
  surname: Kouznetsova
  fullname: Kouznetsova, Tatiana
– sequence: 7
  givenname: Hans-Henning
  surname: Eckstein
  fullname: Eckstein, Hans-Henning
– sequence: 8
  givenname: Uwe
  surname: Heemann
  fullname: Heemann, Uwe
– sequence: 9
  givenname: Jan A
  surname: Staessen
  fullname: Staessen, Jan A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19660101$$D View this record in MEDLINE/PubMed
BookMark eNpNUMlOwzAQtVARXeDKEfkGHAyZxHGSY1WxSQUuvUdeJtQosUOcAvl7IrUgTvM0b5nRm5OJ8w4JOYfoBiAXt8CzlMU5j1jOeHpEZn-LyT88JfMQ3qMIslzACZlCIUQEEcyIX4bgtZW99Y4q7L8QHdWy87011FjZYI8dlc7QfotUmk_pNBr6Vg9678GRajtvdrqnLwzbYGvv2Jig_PcwurdDXQ_BOqRXq-f19Sk5rmQd8OwwF2Rzf7dZPbL168PTarlmbZoCEwKUUqkSqR6vVZVUkUoEiCyJMYGcZ6JKNeSFBKNlhlmRK9ScQ1FhzCEWyYJc7mPH1z52GPqysUFjXUuHfhfKLOFjGXGajcqLg3KnGjRl29lGdkP5W1HyA2IFa0w
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1186/1475-2840-8-45
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1475-2840
ExternalDocumentID 19660101
Genre Journal Article
Comparative Study
GroupedDBID ---
0R~
29B
2VQ
2WC
4.4
53G
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C1A
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
ECM
EIF
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
KQ8
M1P
M48
M~E
NPM
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RBZ
RIG
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
7X8
PUEGO
ID FETCH-LOGICAL-p551-661bbb5b65ccedffab0b3616732e318476f5c189a1dca7e798bec4419fe241263
IEDL.DBID M48
ISSN 1475-2840
IngestDate Thu Sep 04 18:57:09 EDT 2025
Mon Jul 21 05:46:19 EDT 2025
IsPeerReviewed true
IsScholarly true
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p551-661bbb5b65ccedffab0b3616732e318476f5c189a1dca7e798bec4419fe241263
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 19660101
PQID 734017257
PQPubID 23479
ParticipantIDs proquest_miscellaneous_734017257
pubmed_primary_19660101
PublicationCentury 2000
PublicationDate 2009-Aug-06
20090806
PublicationDateYYYYMMDD 2009-08-06
PublicationDate_xml – month: 08
  year: 2009
  text: 2009-Aug-06
  day: 06
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Cardiovascular diabetology
PublicationTitleAlternate Cardiovasc Diabetol
PublicationYear 2009
References 10531386 - J Biol Chem. 1999 Oct 29;274(44):31740-9
16966578 - Hypertension. 2006 Oct;48(4):609-15
9125305 - Atherosclerosis. 1996 Dec 20;127(2):155-65
15258735 - Diabetologia. 2004 Aug;47(8):1376-9
16997053 - Am J Kidney Dis. 2006 Oct;48(4):571-9
19508707 - Crit Care. 2009;13(3):R87
16408126 - Kidney Int. 2006 Jan;69(2):350-7
18645498 - Transplantation. 2008 Jul 27;86(2):330-5
15136058 - Atherosclerosis. 2004 Jun;174(2):287-92
11581294 - J Clin Invest. 2001 Oct;108(7):949-55
7887450 - Am J Pathol. 1995 Mar;146(3):688-94
16138562 - Hypertens Res. 2005 Apr;28(4):323-9
12629447 - Diabetes Metab. 2003 Feb;29(1):44-52
11522709 - Diabetes Care. 2001 Sep;24(9):1620-3
16952987 - Circulation. 2006 Sep 12;114(11):1185-92
11119472 - Heart. 2001 Jan;85(1):87-91
15164755 - Biochim Biophys Acta. 2004 Mar 22;1636(2-3):82-9
16915020 - J Hypertens. 2006 Sep;24(9):1719-27
9182719 - Biochem J. 1997 Jun 1;324 ( Pt 2):565-70
17324733 - Am J Hypertens. 2007 Mar;20(3):242-7
16037256 - Ann N Y Acad Sci. 2005 Jun;1043:343-54
15882283 - Kidney Int. 2005 Jun;67(6):2383-92
16969649 - Diabetologia. 2006 Nov;49(11):2756-62
17241110 - Am J Transplant. 2007 Feb;7(2):293-302
12642050 - Lancet. 2003 Mar 8;361(9360):827-33
18310969 - Intern Med. 2008;47(5):391-8
15851628 - Hypertension. 2005 Jul;46(1):232-7
3082871 - J Biol Chem. 1986 Apr 15;261(11):4889-94
18335040 - PLoS One. 2008;3(3):e1765
10393704 - J Clin Invest. 1999 Jul;104(1):103-13
17223995 - Clin Endocrinol (Oxf). 2007 Feb;66(2):246-50
19118493 - Clin Sci (Lond). 2009 Feb;116(3):219-30
10500038 - Circulation. 1999 Sep 28;100(13):1387-93
16936331 - Rheumatology (Oxford). 2007 Mar;46(3):412-6
9129235 - J Invest Dermatol. 1997 May;108(5):797-802
19110009 - Regul Pept. 2009 Apr 10;154(1-3):39-43
10338462 - Circulation. 1999 May 25;99(20):2677-81
9287050 - Diabetes. 1997 Sep;46(9):1481-90
References_xml – reference: 10500038 - Circulation. 1999 Sep 28;100(13):1387-93
– reference: 16997053 - Am J Kidney Dis. 2006 Oct;48(4):571-9
– reference: 17241110 - Am J Transplant. 2007 Feb;7(2):293-302
– reference: 12642050 - Lancet. 2003 Mar 8;361(9360):827-33
– reference: 10531386 - J Biol Chem. 1999 Oct 29;274(44):31740-9
– reference: 19508707 - Crit Care. 2009;13(3):R87
– reference: 18310969 - Intern Med. 2008;47(5):391-8
– reference: 10393704 - J Clin Invest. 1999 Jul;104(1):103-13
– reference: 16408126 - Kidney Int. 2006 Jan;69(2):350-7
– reference: 16138562 - Hypertens Res. 2005 Apr;28(4):323-9
– reference: 17324733 - Am J Hypertens. 2007 Mar;20(3):242-7
– reference: 16037256 - Ann N Y Acad Sci. 2005 Jun;1043:343-54
– reference: 16969649 - Diabetologia. 2006 Nov;49(11):2756-62
– reference: 18335040 - PLoS One. 2008;3(3):e1765
– reference: 11522709 - Diabetes Care. 2001 Sep;24(9):1620-3
– reference: 16915020 - J Hypertens. 2006 Sep;24(9):1719-27
– reference: 7887450 - Am J Pathol. 1995 Mar;146(3):688-94
– reference: 11581294 - J Clin Invest. 2001 Oct;108(7):949-55
– reference: 15851628 - Hypertension. 2005 Jul;46(1):232-7
– reference: 16966578 - Hypertension. 2006 Oct;48(4):609-15
– reference: 15136058 - Atherosclerosis. 2004 Jun;174(2):287-92
– reference: 9129235 - J Invest Dermatol. 1997 May;108(5):797-802
– reference: 15258735 - Diabetologia. 2004 Aug;47(8):1376-9
– reference: 3082871 - J Biol Chem. 1986 Apr 15;261(11):4889-94
– reference: 9125305 - Atherosclerosis. 1996 Dec 20;127(2):155-65
– reference: 9287050 - Diabetes. 1997 Sep;46(9):1481-90
– reference: 12629447 - Diabetes Metab. 2003 Feb;29(1):44-52
– reference: 19110009 - Regul Pept. 2009 Apr 10;154(1-3):39-43
– reference: 15164755 - Biochim Biophys Acta. 2004 Mar 22;1636(2-3):82-9
– reference: 15882283 - Kidney Int. 2005 Jun;67(6):2383-92
– reference: 11119472 - Heart. 2001 Jan;85(1):87-91
– reference: 16952987 - Circulation. 2006 Sep 12;114(11):1185-92
– reference: 19118493 - Clin Sci (Lond). 2009 Feb;116(3):219-30
– reference: 16936331 - Rheumatology (Oxford). 2007 Mar;46(3):412-6
– reference: 10338462 - Circulation. 1999 May 25;99(20):2677-81
– reference: 17223995 - Clin Endocrinol (Oxf). 2007 Feb;66(2):246-50
– reference: 9182719 - Biochem J. 1997 Jun 1;324 ( Pt 2):565-70
– reference: 18645498 - Transplantation. 2008 Jul 27;86(2):330-5
SSID ssj0017861
Score 1.8170006
Snippet Nepsilon-carboxymethyllysine (CML) is the major non-cross linking advanced glycation end product (AGE). CML is elevated in diabetic patients and apparent in...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 45
SubjectTerms Adult
alpha-2-HS-Glycoprotein
Anthropometry
Belgium - epidemiology
Biomarkers
Blood Proteins - analysis
Carotid Arteries - chemistry
Carotid Arteries - diagnostic imaging
Carotid Arteries - ultrastructure
Carotid Artery Diseases - blood
Carotid Artery Diseases - complications
Carotid Artery Diseases - diagnostic imaging
Carotid Artery Diseases - pathology
Carotid Artery Diseases - surgery
Cohort Studies
Elasticity
Female
Glycation End Products, Advanced - blood
Humans
Hypertension - complications
Inflammation
Lysine - analogs & derivatives
Lysine - blood
Male
Mechanotransduction, Cellular
Middle Aged
Sampling Studies
Tunica Intima - ultrastructure
Ultrasonography
Title Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML)
URI https://www.ncbi.nlm.nih.gov/pubmed/19660101
https://www.proquest.com/docview/734017257
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3NS8MwFA-6gXgRv50fIwcPeoi2a9qkB5E5NsawQ3SD3UrSpjKobd0HrP-9L23HBBVPPTRp4feS934vv_AeQtcub0kuQkkCEUlCbRkRaULOoxS4S2VQGRTdG7yh0x_TwcSebO4_VQDOf03tdD-p8Sy-W33mj7DhH4oNz517kzKbgJs1CIe_baM6RCVHJ2Ie3SgKjJe1U9djqwKOP-f_TTWLkNPbR3sVV8Tt0rgHaEslh2jHq9TwI5R-wxZXF66w7sOzmIYY7P6hr7pgkYQYWB5eq_34Pc7Lczqs4FVWlnzFQ6Ky-TROE8BzJtNVrntL57GuWJIofNPxnm-P0ajXHXX6pGqgQDIgQgRCr5TSlo4dwNejSEhDWg5AY7X0ySdlTmQHJneFGQaCKeZyMCjQIzdSgGDLsU5QLUkTdYZwpAVDm1FumRJGRJKZNBRccUGVckO3gfAaNB_WpxYdRKLS5dxnFtVpps0a6LQE08_KOhq-qSuDgks4_3_yBdotZRxODOcS1RazpboCNrCQTbTNJqyJ6u324G0Az6fu8OW1WeTWzWIJfAHP8biw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+carotid+diameter+and+the+advanced+glycation+end+product+N-epsilon-carboxymethyllysine+%28CML%29&rft.jtitle=Cardiovascular+diabetology&rft.au=Baumann%2C+Marcus&rft.au=Richart%2C+Tom&rft.au=Sollinger%2C+Daniel&rft.au=Pelisek%2C+Jaroslav&rft.date=2009-08-06&rft.issn=1475-2840&rft.eissn=1475-2840&rft.volume=8&rft.spage=45&rft_id=info:doi/10.1186%2F1475-2840-8-45&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2840&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2840&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2840&client=summon